BIOMAT Database Logo BIOMAT Database Logo

Sequential release of bioactive IGF-I and TGF-beta 1 from PLGA microsphere-based scaffolds. 2008

Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Center for Biomedical Engineering, Brown University, Providence, RI 02912, USA.

Growth factors have become an important component for tissue engineering and regenerative medicine. Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta1 (TGF-beta 1) in particular have great significance in cartilage tissue engineering. Here, we describe sequential release of IGF-I and TGF-beta 1 from modular designed poly(l,d-lactic-co-glycolic acid) (PLGA) scaffolds. Growth factors were encapsulated in PLGA microspheres using spontaneous emulsion, and in vitro release kinetics was characterized by ELISA. Incorporating BSA in the IGF-I formulations decreased the initial burst from 80% to 20%, while using uncapped PLGA rather than capped decreased the initial burst of TGF-beta 1 from 60% to 0% upon hydration. The bioactivity of released IGF-I and TGF-beta 1 was determined using MCF-7 proliferation assay and HT-2 inhibition assay, respectively. Both growth factors were released for up to 70 days in bioactive form. Scaffolds were fabricated by fusing bioactive IGF-I and TGF-beta 1 microspheres with dichloromethane vapor. Three scaffolds with tailored release kinetics were fabricated: IGF-I and TGF-beta 1 released continuously, TGF-beta 1 with IGF-I released sequentially after 10 days, and IGF-I with TGF-beta 1 released sequentially after 7 days. Scaffold swelling and degradation were characterized, indicating a peak swelling ratio of 4 after 7 days of incubation and showing 50% mass loss after 28 days, both consistent with scaffold release kinetics. The ability of these scaffolds to release IGF-I and TGF-beta 1 sequentially makes them very useful for cartilage tissue engineering applications.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008863 Microspheres Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers. Latex Beads,Latex Particles,Latex Spheres,Microbeads,Bead, Latex,Beads, Latex,Latex Bead,Latex Particle,Latex Sphere,Microbead,Microsphere,Particle, Latex,Particles, Latex,Sphere, Latex,Spheres, Latex
D011100 Polyglycolic Acid A biocompatible polymer used as a surgical suture material. Polyglycolide,Biofix,Dexon (Polyester),Dexon-S,Dexon S,DexonS
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077182 Polylactic Acid-Polyglycolic Acid Copolymer A co-polymer that consists of varying ratios of polylactic acid and polyglycolic acid. It is used as a matrix for drug delivery and for BONE REGENERATION. PLGA Acid,LactoSorb,PL-PG Copolymer,PLG Polymer,PLGA Compound,Poly (D,L-lactic-co-glycolic Acid),Poly (Lactic-co-glycolic Acid) -,Poly(D,L-lactide-co-glycolide),Poly(DL-lactide-co-glycolic Acid),Poly(Glycolide-co-lactide),Poly(L-lactide)-co-glycolide,Poly(Lactic-co-glycolic Acid),Poly-L-lactic-polyglycolic Acid,Polylactic-co-glycolic Acid Copolymer,RG 502,Acid, PLGA,Acids, PLGA,Copolymer, PL-PG,Copolymer, Polylactic-co-glycolic Acid,Copolymers, PL-PG,Copolymers, Polylactic-co-glycolic Acid,PL PG Copolymer,PL-PG Copolymers,PLG Polymers,PLGA Acids,PLGA Compounds,Poly L lactic polyglycolic Acid,Poly-L-lactic-polyglycolic Acids,Polylactic Acid Polyglycolic Acid Copolymer,Polylactic co glycolic Acid Copolymer,Polylactic-co-glycolic Acid Copolymers,Polymer, PLG,Polymers, PLG
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Bioactive Microsphere-Based Scaffolds Containing Decellularized Cartilage.
July 2015, Macromolecular bioscience,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Sequential IGF-1 and BMP-6 releasing chitosan/alginate/PLGA hybrid scaffolds for periodontal regeneration.
November 2017, International journal of biological macromolecules,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Sustained release of bioactive IGF-1 from a silk fibroin microsphere-based injectable alginate hydrogel for the treatment of myocardial infarction.
January 2020, Journal of materials chemistry. B,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Controlled release of TGF-beta 1 from RADA self-assembling peptide hydrogel scaffolds.
January 2016, Drug design, development and therapy,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Controlled release of bioactive TGF-beta 1 from microspheres embedded within biodegradable hydrogels.
March 2006, Biomaterials,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Effect of glutamine on glutathione, IGF-I, and TGF-beta 1.
May 2003, The Journal of surgical research,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Treatment of growth plate injury using IGF-I-loaded PLGA scaffolds.
December 2015, Journal of tissue engineering and regenerative medicine,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Release of fibroblast IGFBPs by TGF-beta and IGF-I occurs through distinct mechanisms.
March 1993, Growth regulation,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
PLGA microsphere construct coated with TGF-beta 3 loaded nanoparticles for neocartilage formation.
August 2008, Biomacromolecules,
Ana Jaklenec, and Alexandra Hinckfuss, and Bahar Bilgen, and Deborah M Ciombor, and Roy Aaron, and Edith Mathiowitz
Release of PLGA-encapsulated dexamethasone from microsphere loaded porous surfaces.
January 2010, Journal of materials science. Materials in medicine,
Copied contents to your clipboard!